Ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, has shown promising results in a phase 3 trial for adolescents and adults with moderate to severe eczema. The medication significantly improved skin symptoms, itch reduction, and quality of life, with a manageable safety profile. The trial involved 336 patients aged 12 to 75 years and demonstrated efficacy as early as day 3 of treatment.

Source: JAMA Dermatology